Description

Globus Medical: Expansion of Core Spine and Product Portfolio & Critical Growth Levers!

Globus Medical recently released their third quarter 2025 financial results, providing insights into their strategic performance and financial health. The company’s revenue reached $769 million, a 22.9% increase from the previous year, and their non-GAAP diluted earnings per share rose robustly by 42.6% to $1.18. This growth was primarily driven by significant gains in the U.S. Spine business and contributions from their recent acquisition of the Nevro business, which added $99.3 million in revenue. Positive aspects include a solid performance by Globus Medical’s U.S. Spine business, growing 9.6% year-over-year, showing 32 weeks of consecutive growth. Their Enabling Technologies division, although facing a 27% decline in revenues, has a pipeline that remains positive with a focus on capital deal structures emphasizing flexibility. Internationally, growth remained moderate at 5.6%, with noteworthy sales improvements in key markets like Australia and Japan. The company’s Trauma business reported an impressive 17.